Invesco

Q3 2026
as of September 30, 2026

Invesco Health Care Fund

A: GGHCX | R6: GGHSX | Y: GGHYX

Why invest in this fund

1. **Focus on premier companies.** We seek to identify industry-leading health care companies that we believe can grow at above-average rates.
2. **Disciplined approach.** Our team utilizes a rigorous risk management and sell discipline in an effort to outperform the benchmark.
3. **Experienced team.** Our depth of experience helps us to consistently execute our investment process across a variety of market conditions.

Top issuers
(% of total market value)

Eli Lilly & Co	10.57
Johnson & Johnson	6.92
Merck & Co Inc	5.08
UnitedHealth Group Inc	5.07
AbbVie Inc	4.24
Gilead Sciences Inc	3.50
Argenx SE	3.39
Thermo Fisher Scientific Inc	3.12
Vertex Pharmaceuticals Inc	2.56
Welltower Inc	2.32

Holdings are subject to change and are not buy/sell recommendations.

Portfolio characteristics

Total number of holdings	76
Weighted avg mkt cap	$253,365 million

Asset mix

Dom Common Stock	91.06
Intl Common Stock	7.72
Cash	1.21

What this fund does

The fund seeks to provide long-term growth of capital by investing in global health care companies that we believe are industry leaders and pioneers with high-quality management teams.

Fund overview (as of 09/30/26)

Fund objective	The fund seeks long-term growth of capital.
Total net assets	$1,218.97 million
Distribution frequency	Yearly
Morningstar category	Health
Portfolio managers	Joy Budzinski, Justin Livengood
Annual turnover (as of 10/31/25)	59%

Top industries (% of total market value)



Top countries (% of total market value)



Not a Deposit; Not FDIC Insured; Not Guaranteed by the Bank; May Lose Value; Not Insured by any Federal Government Agency

For more information, including prospectus and commentary, please visit Invesco.com/GGHCX

Performance of a $10,000 investment ($)

Class A shares at NAV (September 30, 2016 – September 30, 2026)

■ Invesco Health Care Fund Class A at NAV: $20,739



Fund statistics fund vs. index

	3 years	5 years
Alpha (%)	-0.36	-3.20
Beta	0.92	1.00
R-squared	0.87	0.88
Sharpe ratio	0.43	-0.01
Tracking error	5.22	5.44
Up capture (%)	90.18	88.85
Down capture (%)	95.20	105.50
	Fund	**Index**
3-Year standard deviation	13.94	14.01

Expense ratios

	% net	% total
Class A	1.07	1.07
Class R6	0.72	0.72
Class Y	0.82	0.82

Per the current prospectus.

Standardized performance (%) as of September 30, 2026

		YTD	3 month	1 year	3 year	5 year	10 year	Since Inception
Class A shares inception: 08/07/89	NAV	4.77	0.97	12.77	10.33	3.53	7.57	9.94
	Max. Load 5.5%	-0.98	-4.59	6.55	8.28	2.36	6.96	9.77
Class R6 shares inception: 04/04/17	NAV	5.07	1.08	13.17	10.72	3.88	7.90	-
Class Y shares inception: 10/03/08	NAV	4.99	1.04	13.06	10.61	3.79	7.84	9.48
S&P Composite 1500 Health Care Index (USD)		10.80	6.26	23.26	11.33	7.10	10.74	-
Total return ranking vs. Morningstar Health category (Class A shares at NAV)		-	-	88% (154 of 170)	78% (124 of 160)	67% (118 of 153)	91% (110 of 121)	-

Calendar year total returns (%)

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Class A shares at NAV	-11.71	15.46	0.46	32.00	14.45	12.19	-13.53	3.05	3.97	15.49
S&P Composite 1500 Health Care Index (USD)	-2.05	22.47	6.71	20.87	14.55	24.85	-3.31	1.92	2.81	13.71

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit invesco.com for the most recent month-end performance. Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary so that you may have a gain or a loss when you sell shares. Returns less than one year are cumulative; all others are annualized. Performance shown prior to the inception date of Class R6 shares is that of Class A shares and includes the 12b-1 fees applicable to Class A shares. Index source: RIMES Technologies Corp. Had fees not been waived and/or expenses reimbursed in the past, returns would have been lower. Performance shown at NAV does not include the applicable front-end sales charge, which would have reduced the performance.

Class Y and R6 shares have no sales charge; therefore performance is at NAV. Class Y shares are available only to certain investors. Class R6 shares are closed to most investors. Please see the prospectus for more details.

The S&P Composite 1500® Health Care Index comprises those companies included in the S&P Composite 1500 that are classified as members of the GICS® Health Care sector.

About Risk

In general, stock and other equity securities values fluctuate, sometimes widely, in response to activities specific to the company as well as general market, economic and political conditions.

Convertible securities may be affected by market interest rates, the risk of issuer default, the value of the underlying stock, or the issuer's right to buy back the convertible securities.

Derivatives may be more volatile and less liquid than traditional investments and are subject to market, interest rate, credit, leverage, counterparty, and management risks. An investment in a derivative could lose more than the cash amount invested.

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

The performance of an investment concentrated in issuers of a certain region or country is expected to be closely tied to conditions within that region and to be more volatile than more geographically diversified investments.

The health care industry is subject to risks relating to government regulation, obsolescence caused by scientific advances and technological innovations.

Preferred securities may include provisions that permit the issuer to defer or omit distributions for a certain period of time, and reporting the distribution for tax purposes may be required, even though the income may not have been received. Further, preferred securities may lose substantial value due to the omission or deferment of dividend payments.

Stocks of small and medium-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risks associated with an investment in the Fund.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Note: Not all products available at all firms. Financial professionals, please contact your home office.

The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

Alpha (cash adjusted) is a measure of performance on a risk-adjusted basis. **Beta** (cash adjusted) is a measure of relative risk and the slope of regression. **R-squared** is the percentage of a fund or security's movements that can be explained by movements in a benchmark index. **Sharpe Ratio** is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk. A higher Sharpe ratio indicates better risk-adjusted performance. **Standard deviation** measures a fund's range of total returns and identifies the spread of a fund's short-term fluctuations. **Tracking Error** is defined as the expected standard deviation of a portfolio's excess return over the benchmark index return. The **up and down capture** measures how well a manager was able to replicate or improve on periods of positive benchmark returns and how severely the manager was affected by periods of negative benchmark returns.

Morningstar

Source: ©2026 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Past performance is no guarantee of future results. Open-end mutual funds and exchange-traded funds are considered a single population for comparison purposes. For factsheets that display Morningstar Star Ratings; Ratings are calculated for funds with at least a three year history. The overall rating is derived from a weighted average of three-, five- and 10- year rating metrics, as applicable, excluding sales charges and including fees and expenses. Had fees not been waived and/or expenses reimbursed currently or in the past, the Morningstar rating would have been lower. Ratings are as of the most recent quarter end and are subject to change every month. The top 10% of fund in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. Ratings for other share classes may differ due to different performance characteristics.

Before investing, consider the Fund's investment objectives, risks, charges and expenses. Visit invesco.com/fundprospectus for a prospectus/summary prospectus containing this information. Read it carefully before investing.